These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7569514)

  • 1. An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.
    Wakefield J; Racine-Poon A
    Stat Med; 1995 May 15-30; 14(9-10):971-86. PubMed ID: 7569514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Errors-in-variables in joint population pharmacokinetic/pharmacodynamic modeling.
    Bennett J; Wakefield J
    Biometrics; 2001 Sep; 57(3):803-12. PubMed ID: 11550931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical methods for population pharmacokinetic modelling.
    Racine-Poon A; Wakefield J
    Stat Methods Med Res; 1998 Mar; 7(1):63-84. PubMed ID: 9533262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of predictive probabilities in phase II and phase III clinical trials.
    Johns D; Andersen JS
    J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints.
    Whitehead J; Zhou Y; Hampson L; Ledent E; Pereira A
    J Biopharm Stat; 2007; 17(6):1117-29. PubMed ID: 18027220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method.
    Watanabe M; Fukuoka N; Takeuchi T; Yamaguchi K; Motoki T; Tanaka H; Kosaka S; Houchi H
    Biol Pharm Bull; 2014; 37(6):916-21. PubMed ID: 24882404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.
    Triggs EJ; Charles BG; Contin M; Martinelli P; Cortelli P; Riva R; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1996; 51(1):59-67. PubMed ID: 8880053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative in vitro study of anticoagulant activity of RA36 DNA aptamer in human, rabbit, and rat blood plasma].
    Savchik EIu; Kalinina TB; Drozd NN; Makarov VA; Zav'ialova EG; Lapsheva EN; Babiĭ AV; Mudrik NN; Pavlova GV; Golovin AV; Kopylov AM
    Eksp Klin Farmakol; 2012; 75(11):13-8. PubMed ID: 23323327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian population modeling of drug dosing adherence.
    Fellows K; Stoneking CJ; Ramanathan M
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):515-25. PubMed ID: 26319548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.